Fluoroquinolone prophylaxis during haematopoietic cell transplantation (HCT) can lead to antimicrobial resistance (AMR). Identifying the groups of patients that have the highest likelihood of benefiting from prophylactic antimicrobials is important for antimicrobial stewardship (AMS). We aimed to identify groups of HCT recipients that have the highest likelihood of benefiting from prophylactic fluroquinolones.
View Article and Find Full Text PDFObjectives: Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance.
Methods: All admission episodes for HCT ( = 400 , 372 unique patients) in a tertiary centre between January 2020 and December 2022 were studied.